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Background: Recent studies suggest that immunophenotypic remission (IR) may be a relevant 
prognostic factor in patients with multiple myeloma (MM). However, data on this role after 
allografting are lacking. Aim: To evaluate the impact of IR and compare it to conventional 
complete remission (CR) in myeloma patients treated with an allograft. Methods: Sixty-six 
consecutive patients, median age 54 years (35-66), who underwent an allograft between January 
2000 and December 2011 with a follow-up of at least 3 months were included. Disease response 
was evaluated by serum and urine electrophoresis, and bone marrow aspirate at 3, 6, 12, 18, 24 
months after transplant and yearly thereafter. Skeletal survey or MRI were performed yearly or as 
clinically indicated (overt relapse or complaints of bone pain). Bone marrow aspirates had to 
contain at least 13000 cells/µL for flow cytometry studies and IR was defined as absence of 
monoclonal plasmacells detected by 4 or 6-colour staining with the following antibodies: CD38, 
CD138, CD56, CD19, CD45, cyKappa, cyLambda. CR was defined according to standard criteria 
(Leukemia. 2006;20:1467-73). Results: Conditioning regimen was non-myeloablative 2Gy TBI-
based in 55 patients, reduced intensity (fludarabine-melphalan-based) in 10 and myeloablative in 1 
patient. Post-grafting immunosuppression consisted of cyclosporine with mycophenolate mofetil or 
methotrexate. Donors were HLA identical siblings in 58 patients and unrelated in 8. Only 1 patient 
received bone marrow as source of stem cells. Thirty-five/66 (53%) received the allograft as part of 
the first line treatment, whereas the others (31/66, (47%) were transplanted after disease relapse. 
Among patients surviving at least 3 months, treatment related mortality was 10.6% at 3 years. After 
a median follow-up of 69 months (range 19-147), the incidence of acute and chronic graft-versus-
host disease was 45.6% and 49.3%, without significant difference between responsive and non-
responsive patients. At follow-up, 24 patients achieved CR and IR (CR/IR), 22 achieved IR but not 
CR because of persistence of urine/serum M-component (noCR/IR), and 20 did not achieve either 
CR or IR (noCR/noIR). Interestingly, none achieved CR without IR. Median overall (OS) and 
event-free survivals (EFS) were not reached and 59 months in the CR/IR group, 77 and 15 months 
in the noCR/IR, and 30 and 5 months in the noCR/noIR respectively (p<0.001 for both OS and 
EFS). Being in the CR/IR group was the only significant predictor for prolonged OS and EFS 
(p<0.001). Of note, the cumulative incidence of extramedullary disease at first relapse after the 
allograft was 4.4% in the CR/IR, 31.8% in the noCR/IR and 15.0% in the noCR/noIR groups 
respectively(p<0.001). Receiving the allograft as first line therapy or later during the disease course 
did not significantly impact on OS and EFS. Conclusions: The achievement of IR showed a 
significant impact on clinical outcomes including patients who did  not clear the M-component. 
Discrepancies between IR and CR, observed in the noCR/IR group (some 30% of our patient 
cohort) along with a higher incidence of extramedullary relapse, suggest that myeloma cells may 
escape immune control outside the bone marrow. In this group, imaging studies such as positron 
emission tomography may be indicated to allow detection of early relapse.   
 
 
 
